Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs

Robert S Epstein
Epstein Health, LLC, Woodcliff Lake, NJ, USA

Abstract: The coronavirus disease 2019 (COVID-19) pandemic has brought increased attention to vulnerable populations such as older or immunocompromised patients and heightened the focus on alternatives to intravenous (IV) formulations, particularly those that may be administered in a non-clinical setting. Among these alternative formulations are subcutaneous (SC) injections, which comprise an increasing share of commercialized and pipeline therapies. While much has been published about the benefits and limitations of IV versus SC administration to patients and health systems, less attention has been given to payer considerations regarding these routes of administration. Accordingly, this article provides payer perspectives on some of the key differences between IV and SC administration as they relate to management and billing, cost, treatment adherence and safety, and patient preference and quality of life. The benefits and limitations of these drug administration routes to key healthcare stakeholders—namely patients, physicians, and payers—are also discussed. Considerations of relevance are highlighted, including the potential for misalignment of stakeholder interests and countervailing factors that may impact decision-making about IV and SC formulations.

Keywords: drug utilization management, formularies, pharmacy benefits management

Introduction
The coronavirus disease 2019 (COVID-19) pandemic has heightened the sensitivity of patients, healthcare professionals (HCPs), and payers to outpatient intravenous (IV) infusion treatments due to concerns about exposing vulnerable patients to serious infection. Organizations such as The National Home Infusion Association have suggested that patients use alternative routes of administration, including intramuscular or subcutaneous (SC) injections, where clinically appropriate.\(^1\) In the context of cancer care, it has been advised that HCPs consider alternative treatments to infusions, including the use of oral cancer therapies, with telehealth visits where appropriate in order to minimize the threat of contracting COVID-19.\(^2\)

There are many other reasons beyond the COVID-19 pandemic for payers to consider the growing injectable space and alternative management strategies where clinically appropriate. In recent years, there has been a noticeable increase in the number of injectable drugs in the marketplace.\(^3\) A recent evaluation of the global research and development pipeline by delivery route in 2019 revealed that 55% of all products being studied for pre-regulatory approval are injectable drugs.\(^4\) Additionally, an analysis of 2018 US prescription sales data from the IQVIA National Sales Perspective Database showed that the top three drugs by expenditure were injectables (adalimumab, insulin glargine, and etanercept) and...
accounted for $36.4 billion of the $476.2 billion in total drug expenditure. In the injectables space, there has also been an increasing trend towards SC delivery of therapeutic proteins versus IV administration (Figure 1). Although much has been published about the benefits and limitations of IV versus SC administration to patients and health systems, less attention has been given to payer considerations regarding these routes of administration. The purpose of this article is to provide payer perspectives on some of the key differences between IV and SC administration; highlight some of the key benefits and limitations of these formulations to patients, physicians, and payers; and propose considerations of relevance to payers.

**Coding, Management, and Billing Implications of IV vs SC Formulations**

In the United States, IV and SC drugs are differently coded, adjudicated, managed, and billed; these differences have material implications for payers. Most drugs that are administered via the SC route (particularly those that are self-administered) fall under the pharmacy benefit management (PBM) system, which permits payers to have complete visibility into: (1) the labeler (manufacturer/distributor); (2) the specific product strength, dosage form, and formulation; and, (3) the trade package size and types via the assigned National Drug Code (NDC), a unique 10-digit, 3-segment number assigned to a SC product upon approval by the US Food and Drug Administration (FDA) (Table 1). The transparency of NDC billing enables easier adjudication and time-sensitive management of claims and also allows for more accurate billing and better cost management.

IV-administered drugs generally fall under the health plan management system and are coded using the Healthcare Common Procedure Coding System (HCPCS) (Table 1). HCPCS codes are not as specific and transparent as NDC codes; are updated on a quarterly basis (in contrast to NDC codes which are updated monthly); and have delayed timing of data availability post-drug launch, which may impact the timeliness of claims submissions (Table 1). Coding for IV-administered drugs is more complex as it may require additional reporting of associated services and the application of a complex series of rules to define the total billable infusion time. Given these complexities, some payers prefer to manage their utilization of injectable therapies whenever possible using the PBM system, where formulary adherence, prior authorization in real-time, step therapy mandates, patient copayment, and a variety of other management techniques are more easily and quickly achieved. Payers, including United Healthcare, are increasingly mandating or requesting that the NDC billing format be applied to all physician claims, although this is not universal.

**Figure 1 Subcutaneous versus intravenous monoclonal antibody approvals in the United States from 2000 to 2019.** Figure classification counts different formulations and combination devices for a given mAb as separate product approvals. Adapted from Adv Drug Deliv Rev, Sanchez-Felix M, Burke M, Chen HK, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Copyright (2020), with permission from Elsevier.

**Abbreviations:** IV, intravenous; mAb, monoclonal antibody; SC, subcutaneous.
**Table 1** Some of the Key Differences in Coding, Adjudication, Management, and Billing Between IV and SC Administered Drugs

<table>
<thead>
<tr>
<th>Features</th>
<th>IV Administration</th>
<th>SC Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coding</td>
<td>HCPCS codes</td>
<td>NDC codes</td>
</tr>
<tr>
<td>Specificity of coding</td>
<td>Non-specific</td>
<td>Specific</td>
</tr>
<tr>
<td>Timing of data availability</td>
<td>Delayed</td>
<td>Immediate</td>
</tr>
<tr>
<td>Visibility</td>
<td>Often not transparent</td>
<td>Fully transparent</td>
</tr>
<tr>
<td>Setting</td>
<td>Office/outpatient hospital – extra costs and codes</td>
<td>Home – no additional costs</td>
</tr>
<tr>
<td>Provider services/costs</td>
<td>Nurse/MD injection codes</td>
<td>None if self-injectable</td>
</tr>
</tbody>
</table>

**Abbreviations:** HCPCS, Healthcare Common Procedure Coding System; IV, intravenous; NDC, National Drug Code; SC, subcutaneous.

**Cost Implications of IV vs SC Formulations**

Transitioning from IV to SC administration can offer distinct cost advantages to payers. Firstly, in contrast to IV infusions, many SC medications (eg, rituximab and belimumab) do not require premedication, resulting in direct cost savings. For example, an analysis of the cost of IV infusion therapy for rheumatoid arthritis delivered in a hospital-based infusion center estimated premedication costs per infusion at $7 and $19 (2017 US dollars) for infliximab and rituximab, respectively. When applied to a large patient volume, premedication can have a considerable impact on the cost of care. Moreover, in a claims analysis of the Medco Health Solutions PBM database comprising 1090 US patients treated with biologics for rheumatoid arthritis (SC-administered etanercept and adalimumab, and IV-administered infliximab and abatacept), the cost per effectively-treated patient was approximately $16,000 less with the SC medications versus IV. Likewise, an evaluation of the budget impact of the introduction of SC rituximab to US health plans found that switching cancer patients from IV to SC rituximab reduced total pharmacy and administration costs by $223,000 for commercial health plans in the year with the highest conversion rate. Similar findings with oncology biologics have been reported across countries and study centers despite differences in healthcare systems and payer types.

Exchanging indirect costs along with direct costs is another important consideration for some payers when comparing IV versus SC delivery. In a study of HER2-positive breast cancer patients in Sweden, the overall societal cost (a combination of direct medical, direct non-medical and indirect costs) of IV trastuzumab was higher than that of hospital-based SC delivery. More patients receiving IV treatment took time off work compared to those on the SC regimen (14% vs 5%; \( p=0.0223 \)). Patient time spent at the hospital was significantly greater with IV than SC administration for initial (101 minutes longer) and subsequent (23 minutes longer) treatments with trastuzumab. Indirect costs arising from production loss and lost leisure time were also higher with IV versus SC delivery for initial (€140 higher) and subsequent (€16 higher) trastuzumab treatments. A pharmacoeconomic analysis of patients in Italy who initially received IV rituximab showed that at-home administration of SC rituximab led to fewer working days lost by patients and caregivers and a marked reduction in travel costs, resulting in a 70% decrease in indirect costs with no compromise to safety or adherence.

**Treatment Adherence and Safety with IV vs SC Formulations**

Out of concern about treatment adherence and managing adverse side effects, some payers may prefer IV administration in a healthcare facility over SC delivery in a non-clinical setting as the former allows for direct observation by HCPs that the patient received the drug as prescribed and enables a prompt response to any adverse events while the patient is present. It should however be noted that SC therapies delivered by newer technologies, such as Bluetooth-enabled wearable devices, enable HCPs to assess and improve adherence in real-time. For instance, the Rebis® autoinjector (Merck KGaA, Darmstadt, Germany) can send injection reminders to patients, log drug administration, and export and analyze data through its companion Mitra® computer application (Merck Serono, Darmstadt, Germany). Such devices may be leveraged for continuous monitoring and personalized education and messaging—all of which can improve patient adherence, safety, and outcomes—and can be utilized in conjunction with specialty pharmacy practices such as outbound calls and targeted messages. The recent changes in physician coding and billing for remote patient monitoring and telehealth incentivize this as well.
administered injections, potentially improving treatment adherence and satisfaction.24 A study of patients with multiple sclerosis receiving interferon beta-1a via SC injection with Rebismart, which has adjustable settings for injection speed and depth of needle insertion,25 reported a median adherence of 96.5% over the 5-year study period.21 This increased adherence was associated with a lower risk of disease relapse. Among multiple sclerosis patients receiving disease-modifying therapies, autoinjector use has been reported as the strongest predictor of treatment adherence at 24 months.25

Importantly, SC administration has been shown to be safe and well-tolerated. For example, in a review of 63 publications investigating the safety of IV and SC biologics approved for cancer treatment, the proportion of studies demonstrating fewer adverse events with SC versus IV was slightly higher than those showing no statistically significant difference. Only two trastuzumab-related studies were found to favor IV administration.16 Moreover, evidence suggests that SC administration may be associated with an improved safety profile in terms of reduced infusion-related reactions compared to IV infusions.26–28 Other methods of venous access such as indwelling catheters have been associated with complications such as infection, migration/malpositioning, bleeding, and thrombosis.29 Given these complications, the feasibility of SC injection as a viable alternative to venous catheterization may be worthy of investigation.

Patient Preference and Quality of Life with IV and SC Formulations

Given their implications for patient satisfaction and treatment adherence, patient quality of life and preference should be an important consideration when making formulary decisions.20 A systematic rapid evidence assessment of the humanistic impact of SC and IV formulations of oncology therapies showed that patients had a clear preference for SC administration and reported better health-related quality of life.16 In a cross-sectional study that switched 43 patients with systemic lupus erythematosus from IV or SC (pre-filled syringe) belimumab to self-administered SC doses via autoinjector, all 21 interviewed patients found the autoinjector convenient.30 Of these, 81% reported a positive experience using the autoinjector.30 Questionnaire responses showed that 76% (32/42) of patients who switched from IV belimumab preferred the autoinjector based on convenience, cost, time savings, and decreased injection pain.30 Autoinjector use also improved daily function as well as the ability to work compared with IV administration.30 Likewise, in a systematic review of randomized controlled trials and crossover studies that evaluated patient preference for SC versus IV formulations, four out of six studies reported a patient preference for SC administration.31 The primary factors underlying this preference were the convenience of in-home treatment and the associated time savings.31 These benefits extend to caregivers as well, with SC dosing alleviating their care burden32 and reducing work absences.20 Despite the aforementioned benefits of SC administration, it should be recognized that IV administration may be preferred by some patients as it facilitates in-person access to and interaction with HCPs in a clinical setting.32

Countervailing Considerations

For payers, managing IV and SC treatment options often involves complex decision-making, as can be illustrated using the example of human immunoglobulins. Immunoglobulins are among the most complex specialty drugs for payers to manage due to the large number of products currently on the market, each with varying doses, formulations, and indications; the prescription of off-label uses; and the differing safety and tolerability of IV (IVIG) and SC immunoglobulin (SCIG) formulations based on patient characteristics and route of administration.33,34 Shifting the site of care to the home setting and switching patients from IVIG to SCIG has been shown to be efficacious and cost-saving, and surveys found that patients with primary immunodeficiencies generally prefer in-home immunoglobulin administration.33 This notwithstanding, immunoglobulin infusions in a clinical setting may still be preferred for some patients, such as those at risk of adverse events and those who are non-adherent to therapy.35 Immunoglobulins underscore the importance of keeping an open formulary that affords HCPs the flexibility to prescribe the formulation best suited to a patient’s needs and circumstances.

Anticipated tradeoffs are another important consideration for payers when evaluating fixed-dose SC formulations against weight-based IV administration. In a simulation analysis evaluating IV and SC rituximab formulations for non-Hodgkin lymphoma treatment in the US, the use of SC rituximab saved time compared to reference IV rituximab (ref-RITUX) and biosimilar IV rituximab (biosim-RITUX), and was generally cheaper.
than ref-RITUX (except for small-sized patients receiving a rapid infusion of the reference therapy).³⁶ However, SC rituximab was more costly versus biosimilar RITUX in small- and average-sized patients (at all levels of biosimilar discount) as well as large-sized patients (at discounts ranging from 24% to 25%).³⁶ In a UK budget impact model assessing the cost of adoption of IV biosim-RITUX and IV biosimilar trastuzumab, the higher administration costs of the IV biosimilars versus SC were offset by lower acquisition costs, resulting in a lower total cost for IV biosimilars.³⁷

Despite the benefits of SC administration to patients and the healthcare system, its wider adoption may be hampered by prevailing health insurance policies and physician reimbursement models. For instance, it has been suggested that higher out-of-pocket costs for self-injectable medications for rheumatoid arthritis may result in stronger patient preference for infusion biologics.³⁸ In the case of physicians, the buy-and-bill model incentivizes them to provide infusion treatments since payers can be billed for the cost of IV drugs administered in a clinical setting. Reimbursement for IV drugs generates considerable revenue, especially for oncology practices.³⁹ An analysis of Medicare data from 2006 to 2009 assessed the factors associated with receipt of a given biologic (IV-administered infliximab vs SC-administered etanercept or adalimumab) in patients with rheumatoid arthritis starting their first anti-tumor necrosis factor therapy.³⁸ The analysis found that stronger physician preference for infused therapies was related to reimbursement and also associated with a greater likelihood of infliximab administration. When physician preference for IV infusions was compared across the lowest to the highest quartiles, the proportion of physicians billing for infusions was 34%, 59%, 80%, and 88%, respectively.³⁸

The incentivization of IV administration may also work against step therapy policies instituted by payers. To limit the utilization of infusion biologics, some payers require failure of SC therapy prior to payment authorization for the IV formulation.⁴⁰,⁴¹ These step therapy policies have notable limitations. Firstly, they have been shown to have an equivocal effect on drug utilization⁴⁰ and, potentially, a limited cost benefit.⁴¹ Furthermore, while step therapy policies may constrain a HCP’s initial product formulation choice, they may have a modest impact on the proportion of patients ultimately receiving IV therapy. These policies may simply delay the patient receiving the provider’s preferred formulation, sometimes resulting in suboptimal care and additional expense.⁴⁰ To improve patient outcomes and experience while reducing costs, it is imperative that efforts are made to address the misalignment of patient, physician, and payer interests concerning IV and SC formulations.

Conclusions

In making decisions about IV and SC therapies, payers must balance multiple considerations, including ease of coding and management, cost implications, patient and provider preference, and the aforementioned countervailing factors. Each drug should be evaluated based on the comparative merits of its IV and SC formulations, with patient well-being as the premier concern. The unintended effects of policies (eg, step therapy, buy-and-bill) impacting SC versus IV treatment choice should be acknowledged and addressed such that patients have access to treatments that best suit their needs and circumstances. Additionally, the specific features and attributes of drug delivery methods and technologies should be considered, recognizing, for instance, that not all SC delivery devices are created alike, and may therefore present distinct value propositions to different healthcare stakeholders. Future research including systematic literature reviews could be conducted to further elucidate the nuanced distinctions between these formulations across various products.

Abbreviations

Biosim-RITUX, biosimilar IV rituximab; COVID-19, coronavirus disease 2019; FDA, Food and Drug Administration; HCP, healthcare professional; HCPCS, Healthcare Common Procedure Coding System; IV, intravenous; IVIG, intravenous immunoglobulin; NDC, National Drug Code; PBM, pharmacy benefit management; ref-RITUX, reference IV rituximab; SC, subcutaneous; SCIG, subcutaneous immunoglobulin.

Acknowledgments

The author would like to thank J. Russell Teagarden, DMH, MA for his advice in conceptualizing some of the payer considerations. Medical writing support, including assisting the author with the development of the manuscript drafts and incorporation of comments, was provided by Grace Jeong, PhD and Akua Adu-Boahene, MD, MPH of Alphabet Health (New York, NY), supported by...
Halozyme Therapeutics, according to Good Publication Practice guidelines (https://www.ismpp.org/gpp3).

Funding
Medical writing support was supported by Halozyme Therapeutics. The author received no honoraria related to the development of this publication.

Disclosure
Dr. Epstein currently serves on the Boards of Directors of Illumina, Fate Therapeutics, and Veracyte. He is Chairman of the Board of Decipher Biosciences. He has consulted with many life science companies including Halozyme, Merck, Boehringer Ingelheim, Astra Zeneca, Sanofi, Gl1 Therapeutics, Taiho, Radius Health, and ICTI. He reports personal fees from Halozyme, personal fees from Gl1 Therapeutics, personal fees from Taiho Oncology, personal fees from Merck, personal fees from Radius Health, personal fees from ICTI, personal fees from Diplomat Pharmacy, outside the submitted work.

References